König R, Schönberger W, Neumann P, Benes P, Grimm W
Kinderklinik, Universität Mainz.
Klin Padiatr. 1987 Nov-Dec;199(6):389-91. doi: 10.1055/s-2008-1026828.
Based on the good results of another author 10 boys with marked pubertal gynecomastia were treated with the antioestrogen Tamoxifen (Nolvadex) at a dose of 20-40 mg/d orally for 2-12 months. In most cases the gynecomastia decreased totally, only two patients experienced palpable subareolar glandular tissue at the end of therapy. Side effects were not noted. During therapy levels of estradiol and testosteron increased, with a more pronounced elevation of estradiol. Basal values of LH and FSH remained nearly unchanged, but LH showed an increased response to LH-RH, which could be explained by the antioestrogenic effect of Tamoxifen at the hypothalamic level. The reduction of breast size in spite of increased estradiol levels on the other hand, suggests that the mean therapeutic effect of tamoxifen is through estrogen receptor blockade of breast tissue.
基于另一位作者的良好研究结果,对10名患有明显青春期男性乳房发育症的男孩使用抗雌激素他莫昔芬(诺瓦得士)进行治疗,口服剂量为20 - 40毫克/天,持续2 - 12个月。在大多数情况下,男性乳房发育症完全减轻,仅两名患者在治疗结束时仍可触及乳晕下腺组织。未观察到副作用。治疗期间,雌二醇和睾酮水平升高,雌二醇升高更为明显。促黄体生成素(LH)和促卵泡生成素(FSH)的基础值几乎保持不变,但LH对促性腺激素释放激素(LH - RH)的反应增强,这可以用他莫昔芬在下丘脑水平的抗雌激素作用来解释。另一方面,尽管雌二醇水平升高,但乳房尺寸减小,这表明他莫昔芬的平均治疗效果是通过阻断乳腺组织中的雌激素受体实现的。